Abstract：【Objective】 To investigate the clinical value of white blood cell/mean platelet volume (WMR) in predicting the long-term prognosis of patients with acute ST-segment elevation myocardial infarction (STEMI). 【Methods】 A total of 161 patients with acute STEMI admitted to the Cardiology Department of our hospital from May 2017 to September 2019 were selected and treated with percutaneous coronary intervention (PCI). The patients were divided into a good prognosis group (n=32) and a poor prognosis group (n=129) based on their clinical prognosis. The clinical indicators of the two groups were compared, and multivariate logistic regression analysis was used to analyze the correlation between clinical indicators and long-term adverse prognosis of acute STEMI patients. The receiver operating characteristic (ROC) curve was used to evaluate the value of relevant clinical indicators in predicting the long-term prognosis of acute STEMI patients. 【Results】 The levels of cTnI, LDL-C, WBC, MPV, and WMR in the good prognosis group were significantly lower than those in the poor prognosis group, but the LVEF was higher than that in the poor prognosis group, with statistically significant differences (P<0.05). Multivariate logistic regression analysis showed that WMR, cTnI, MPV, and LVEF were associated with adverse prognosis in patients with acute STEMI (P<0.05), with odds ratios of 3.41, 5.18, 1.18, and 0.91, respectively. ROC curve analysis showed that cTnI had the highest predictive value for adverse prognosis in STEMI patients, significantly higher than WMR, MPV, and LVEF (P<0.01); WMR had a higher predictive value for adverse prognosis in STEMI patients than MPV and LVEF (P<0.05); the optimal diagnostic threshold of WMR was 0.63. Kaplan-Meier survival curve analysis showed that the survival time without major adverse cardiovascular events (MACEs) in the high WMR group was significantly lower than that in the low WMR group (P=0.033). 【Conclusion】 WMR is a potential clinical indicator for predicting the long-term prognosis of STEMI patients and is worthy of clinical reference.
齐建钢, 柳锡琴. 白细胞/平均血小板体积预测STEMI患者远期预后的临床价值[J]. 医学临床研究, 2024, 41(1): 66-69.
QI Jiangang, LIU Xiqin. Clinical Value of Predicting Long-term Prognosis of STEMI Patients with White Blood Cell/Average Platelet Volume. JOURNAL OF CLINICAL RESEARCH, 2024, 41(1): 66-69.
[1] 段玮丽,宋佳,何东旭,等. 血清同型半胱氨酸水平对急性ST段抬高型心肌梗死患者预后的影响[J].中国医科大学学报,2019,48(10):905-909. [2] 庞轩,顾顺忠,陆洋. 胸痛中心对急性ST段抬高型心肌梗死救治效率及在院期间预后的影响[J].湖南师范大学学报(医学版),2019,16(6):183-186. [3] HAMMOUDEH A J, ALHADDAD I A. Triggers and the onset of acute myocardial infarction[J].Cardiol Rev,2009, 17(6):270-274. [4] SULAIMAN K,AL-ZAKWANI I,PANDURANGA P, et al. Relationship between white blood cell count and in-hospital outcomes in acute coronary syndrome patients from the Middle East[J].Angiology,2012,63(1):24-29. [5] 王若楠,夏晓爽,董琪,等. 白细胞计数/平均血小板体积比值与大动脉粥样硬化性卒中短期转归的相关性[J].国际脑血管病杂志,2018,26(11):807-812. [6] 许云梦,徐晓东,方中,等. 白细胞计数/平均血小板体积比值及中性粒细胞/淋巴细胞比值评估急性冠脉综合征患者介入治疗预后的价值[J].安徽医学,2017,38(1):33-37. [7] 中华医学会心血管病学分会,中华心血管病杂志编辑委员会. 急性ST段抬高型心肌梗死诊断和治疗指南(2019)[J].中华心血管病杂志,2019,47(10):766-783. [8] 王丽杰,韩丹宁.替格瑞洛治疗急性ST段抬高型心肌梗死(STEMI)患者的近期抗血小板疗效及不良反应发生情况[J].医学临床研究,2023,40(5):699-702. [9] 谢炜巍,夏陈海,王汝涛,等.替罗非班联合尼可地尔对急性ST段抬高型心肌梗死患者 PCI术后疗效及对患者心功能的影响[J].医学临床研究,2021,38(8):1256-1258. [10] 陆奕,付强,刘奕,等.中性粒细胞/淋巴细胞比率对急性心肌梗死患者临床并发症的预测价值[J].江苏大学学报(医学版),2020,20(2):177-179. [11] 崔宁,刘丽.外周血白细胞与缺血性卒中[J].国际脑血管病杂志,2016,24(5):459-462. [12] 李佳蓓,黄岚.血小板在动脉粥样硬化血栓形成中的作用[J].中华心血管病杂志,2014,42(2):175-177. [13] DEHGHANI M R, REZAEI Y, TAGHIPOUR-SANI L.White blood cell count to mean platelet volume ratio as a novel non-invasive marker predicting long-term outcomes in patients with non-ST elevation acute coronary syndrome[J].Cardiol J,2015,22(4):437-445.
2024, Vol. 41 
